首页 > 最新文献

Central European Journal of Urology最新文献

英文 中文
Evolving types of pudendal neuromodulation for lower urinary tract dysfunction. 用于治疗下尿路功能障碍的不断演变的阴部神经调控类型。
IF 1.2 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-06 DOI: 10.5173/ceju.2023.86
Stefano Parodi, Harry J Kendall, Carlo Terrone, John Pfa Heesakkers

Introduction: Sacral neuromodulation and posterior tibial nerve stimulation for lower urinary tract dysfunction (LUTD) and overactive bladder yield good and reliable results. However, neuromodulation research is continuously evolving because there is still need for more patient-friendly treatment options in the therapeutic management of LUTD. Pudendal neuromodulation (PNM) has been emerging as a promising alternative treatment option for the last few decades. The aim of this study is to review the current state of the art of PNM.

Material and methods: A wide literature search was conducted in the field of PNM using Medline through the PubMed database and Elsevier using the Scopus database; a critical review of the results was then carried out. PNM has been studied in its various possible aspects: percutaneous PNM, transrectal/transvaginal PNM, and both percutaneous and transcutaneous dorsal genital nerve stimulation.

Results: Each technique was found to result in promising improvements in different clinical outcomes, with some trials reporting even better results than sacral neuromodulation.

Conclusions: As a result of a comparison between the various PNM techniques with both sacral neuromodulation and posterior tibial nerve stimulation, we think that PNM should be seen as seriously promising, and we believe it will expand the treatment options for overactive bladder. Even though several studies accordingly showed PNM to be safe and effective, a systematic review and meta-analysis were not feasible. PNM in its various techniques is a promising treatment for LUTD. Nevertheless, further research is needed to include it in treatment algorithms.

简介:骶神经调控和胫后神经刺激治疗下尿路功能障碍(LUTD)和膀胱过度活动症取得了良好可靠的效果。然而,神经调控研究仍在不断发展,因为在下尿路功能障碍的治疗过程中,仍需要更多方便患者的治疗方案。在过去的几十年中,耻骨神经调控(PNM)已成为一种前景广阔的替代治疗方案。本研究的目的是回顾 PNM 的技术现状:通过 PubMed 数据库的 Medline 和 Scopus 数据库的 Elsevier 对 PNM 领域的文献进行了广泛的搜索;然后对搜索结果进行了严格的审查。PNM 的研究涉及各个方面:经皮 PNM、经直肠/经阴道 PNM 以及经皮和经皮生殖器背神经刺激:结果:每种技术都有望改善不同的临床结果,有些试验报告的结果甚至优于骶神经调控技术:通过对各种膀胱过度活动症治疗技术与骶神经调控术和胫后神经刺激术的比较,我们认为膀胱过度活动症治疗技术前景广阔,相信它将扩大膀胱过度活动症的治疗范围。尽管有多项研究显示 PNM 安全有效,但进行系统回顾和荟萃分析并不可行。各种技术的 PNM 是治疗膀胱过度活动症的一种很有前景的方法。不过,要将其纳入治疗算法,还需要进一步的研究。
{"title":"Evolving types of pudendal neuromodulation for lower urinary tract dysfunction.","authors":"Stefano Parodi, Harry J Kendall, Carlo Terrone, John Pfa Heesakkers","doi":"10.5173/ceju.2023.86","DOIUrl":"https://doi.org/10.5173/ceju.2023.86","url":null,"abstract":"<p><strong>Introduction: </strong>Sacral neuromodulation and posterior tibial nerve stimulation for lower urinary tract dysfunction (LUTD) and overactive bladder yield good and reliable results. However, neuromodulation research is continuously evolving because there is still need for more patient-friendly treatment options in the therapeutic management of LUTD. Pudendal neuromodulation (PNM) has been emerging as a promising alternative treatment option for the last few decades. The aim of this study is to review the current state of the art of PNM.</p><p><strong>Material and methods: </strong>A wide literature search was conducted in the field of PNM using Medline through the PubMed database and Elsevier using the Scopus database; a critical review of the results was then carried out. PNM has been studied in its various possible aspects: percutaneous PNM, transrectal/transvaginal PNM, and both percutaneous and transcutaneous dorsal genital nerve stimulation.</p><p><strong>Results: </strong>Each technique was found to result in promising improvements in different clinical outcomes, with some trials reporting even better results than sacral neuromodulation.</p><p><strong>Conclusions: </strong>As a result of a comparison between the various PNM techniques with both sacral neuromodulation and posterior tibial nerve stimulation, we think that PNM should be seen as seriously promising, and we believe it will expand the treatment options for overactive bladder. Even though several studies accordingly showed PNM to be safe and effective, a systematic review and meta-analysis were not feasible. PNM in its various techniques is a promising treatment for LUTD. Nevertheless, further research is needed to include it in treatment algorithms.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 1","pages":"82-88"},"PeriodicalIF":1.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Summary of guidelines from the Polish Urological Association, Polish Society of Gynaecologists and Obstetricians, and Polish Society of Family Medicine on the diagnosis, therapy, and management of community-acquired lower urinary tract infections.
IF 1.4 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-29 DOI: 10.5173/ceju.2024.01.Guid
Kajetan Juszczak, Bartosz Dybowski, Michał Holecki, Waleria Hryniewicz, Hanna Klimek, Karolina Kłoda, Piotr Sieroszewski, Tomasz Drewa

Introduction: This publication provides a summary of national guidelines developed in response to the regional characteristics of aetiological factors, resistance patterns, and the availability of antibacterial drugs in Poland.

Material and methods: After reviewing the epidemiological evidence, case-control studies, randomised control trials, and current international guidelines and statements, a Polish multidisciplinary group prepared the final recommendations. These recommendations cover diagnosis and management of community-acquired lower urinary tract infections in both genders, pregnant and breastfeeding women, recurrent lower urinary tract infections, and asymptomatic bacteriuria.

Results: The regional choice of antimicrobial agents for first-line therapy of uncomplicated cystitis in women includes fosfomycin trometamol, pivmecillinam, furazidin (furagin), and nitroxoline. For men, co-trimoxazole or fluoroquinolone therapy is recommended. Pivmecillinam and fosfomycin are recommended for the treatment of pregnant and breastfeeding women. For continuous prophylaxis of recurrent urinary tract infections in women, the following antimicrobial agents can be used: fosfomycin trometamol, trimethoprim, furazidin (furagin), and cefaclor. The significance of behavioural management and the use of vaginal hormonal therapy, vaginal probiotics, and immunoprophylaxis is emphasised. Asymptomatic bacteriuria should be treated in pregnant women and in patients prior to surgical intervention in the urinary tract.

Conclusions: New national guidelines based on locally available therapeutic resources should contribute to a more rational choice of therapy in patients with lower urinary tract infection and asymptomatic bacteriuria in Poland.

{"title":"Summary of guidelines from the Polish Urological Association, Polish Society of Gynaecologists and Obstetricians, and Polish Society of Family Medicine on the diagnosis, therapy, and management of community-acquired lower urinary tract infections.","authors":"Kajetan Juszczak, Bartosz Dybowski, Michał Holecki, Waleria Hryniewicz, Hanna Klimek, Karolina Kłoda, Piotr Sieroszewski, Tomasz Drewa","doi":"10.5173/ceju.2024.01.Guid","DOIUrl":"10.5173/ceju.2024.01.Guid","url":null,"abstract":"<p><strong>Introduction: </strong>This publication provides a summary of national guidelines developed in response to the regional characteristics of aetiological factors, resistance patterns, and the availability of antibacterial drugs in Poland.</p><p><strong>Material and methods: </strong>After reviewing the epidemiological evidence, case-control studies, randomised control trials, and current international guidelines and statements, a Polish multidisciplinary group prepared the final recommendations. These recommendations cover diagnosis and management of community-acquired lower urinary tract infections in both genders, pregnant and breastfeeding women, recurrent lower urinary tract infections, and asymptomatic bacteriuria.</p><p><strong>Results: </strong>The regional choice of antimicrobial agents for first-line therapy of uncomplicated cystitis in women includes fosfomycin trometamol, pivmecillinam, furazidin (furagin), and nitroxoline. For men, co-trimoxazole or fluoroquinolone therapy is recommended. Pivmecillinam and fosfomycin are recommended for the treatment of pregnant and breastfeeding women. For continuous prophylaxis of recurrent urinary tract infections in women, the following antimicrobial agents can be used: fosfomycin trometamol, trimethoprim, furazidin (furagin), and cefaclor. The significance of behavioural management and the use of vaginal hormonal therapy, vaginal probiotics, and immunoprophylaxis is emphasised. Asymptomatic bacteriuria should be treated in pregnant women and in patients prior to surgical intervention in the urinary tract.</p><p><strong>Conclusions: </strong>New national guidelines based on locally available therapeutic resources should contribute to a more rational choice of therapy in patients with lower urinary tract infection and asymptomatic bacteriuria in Poland.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"520-527"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of manual hand pump irrigation on intrapelvic temperature during retrograde intrarenal surgery: a thermography-based in vitro study.
IF 1.4 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-05-10 DOI: 10.5173/ceju.2024.98
Krzysztof Balawender, Bartosz Dybowski

Introduction: Thermal injury to kidney tissue during holmium laser lithotripsy represents a significant complication. This issue is often unavoidable due to the variability of renal conditions and the absence of techniques for real-time intrarenal temperature monitoring. The objective of this research was to evaluate influence of manual hand pump irrigation on temperature of the fluid within a pelvicalyceal model during holmium laser lithotripsy.

Material and methods: Laser lithotripsy of artificial stones was carried out in a 3D-printed model of the renal pelvicalyceal system. The irrigation system employed a continuous gravity approach (P = 60 cmH2O), augmented by manual pumping as required. A 9.2 Fr ureteroscope was inserted into the model via a ureteral access sheath (UAS), with sizes of either 10/12 Fr or 12/14 Fr.The power settings for the lithotripsy varied between 12 and 25 W. Temperature monitoring during the procedure was conducted using thermographic methods.

Results: For all laser power settings, the temperatures recorded under gravity irrigation alone were significantly higher compared to those achieved when gravity was combined with a manual hand pump, regardless of the ureteral access sheath size. When using the hand pump system and a 12/14Fr UAS, the median temperatures in none of the laser settings exceeded 30°C. However, using a 10/12Fr UAS, the median temperatures did not exceed 35°C in any of the settings and were significantly lower compared to the use of the gravity flow system alone.

Conclusions: The employment of gravity irrigation supplemented by a manually on-demand pump in retrograde intrarenal surgery is a critical component in mitigating the risk of significant temperature elevations, leading to thermal injury to the adjacent kidney tissues. Moreover, the interquartile ranges of temperatures indicating that gravity system enhanced by an on-demand pump irrigation not only reduce the median temperature but also promote a more consistent thermal environment.

{"title":"Influence of manual hand pump irrigation on intrapelvic temperature during retrograde intrarenal surgery: a thermography-based in vitro study.","authors":"Krzysztof Balawender, Bartosz Dybowski","doi":"10.5173/ceju.2024.98","DOIUrl":"10.5173/ceju.2024.98","url":null,"abstract":"<p><strong>Introduction: </strong>Thermal injury to kidney tissue during holmium laser lithotripsy represents a significant complication. This issue is often unavoidable due to the variability of renal conditions and the absence of techniques for real-time intrarenal temperature monitoring. The objective of this research was to evaluate influence of manual hand pump irrigation on temperature of the fluid within a pelvicalyceal model during holmium laser lithotripsy.</p><p><strong>Material and methods: </strong>Laser lithotripsy of artificial stones was carried out in a 3D-printed model of the renal pelvicalyceal system. The irrigation system employed a continuous gravity approach (P = 60 cmH<sub>2</sub>O), augmented by manual pumping as required. A 9.2 Fr ureteroscope was inserted into the model via a ureteral access sheath (UAS), with sizes of either 10/12 Fr or 12/14 Fr.The power settings for the lithotripsy varied between 12 and 25 W. Temperature monitoring during the procedure was conducted using thermographic methods.</p><p><strong>Results: </strong>For all laser power settings, the temperatures recorded under gravity irrigation alone were significantly higher compared to those achieved when gravity was combined with a manual hand pump, regardless of the ureteral access sheath size. When using the hand pump system and a 12/14Fr UAS, the median temperatures in none of the laser settings exceeded 30°C. However, using a 10/12Fr UAS, the median temperatures did not exceed 35°C in any of the settings and were significantly lower compared to the use of the gravity flow system alone.</p><p><strong>Conclusions: </strong>The employment of gravity irrigation supplemented by a manually on-demand pump in retrograde intrarenal surgery is a critical component in mitigating the risk of significant temperature elevations, leading to thermal injury to the adjacent kidney tissues. Moreover, the interquartile ranges of temperatures indicating that gravity system enhanced by an on-demand pump irrigation not only reduce the median temperature but also promote a more consistent thermal environment.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"512-517"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What kind of water should I advise my kidney stone patient to drink: the Dutch experience. 建议肾结石患者喝什么水:荷兰的经验。
IF 1.4 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.5173/ceju.2024.42.R1
Simone J M Stoots, Michaël M E L Henderickx, Guido M Kamphuis

Introduction: To compare the mineral content of commercially available water (tap and bottled) in the Netherlands and to evaluate which type of water should be recommended for kidney stone patients.

Material and methods: All Dutch water supply companies were contacted to request water analysis reports of tap water. Bottled still and sparkling water available in the 5 main supermarket chains in the Netherlands were also included. Information regarding the mineral composition of bottled waters was read from the manufacturers' ingredient label on the bottles. Data regarding sodium, potassium, bicarbonate, calcium, magnesium, and sulphate content were evaluated.

Results: All Dutch water supply companies, consisting of 179 production locations, were included. Twenty-one bottled still waters and 25 bottled sparkling waters were included. There was a wide range of results for the evaluated minerals. Sodium levels were highest in tap water (134.0 mg/l), whereas potassium concentrations were highest in bottled water (18.0 mg/l). Bicarbonate, calcium, and sulphate concentrations were highest in bottled still water (432.0 mg/l, 240.0 mg/l, and 400.0 mg/l, respectively). Magnesium levels were highest in bottled sparkling water (51.4 mg/l).

Conclusions: Commercially available water (bottled and tap) in the Netherlands is safe to use for KSD patients. However, specific bottled waters can be described as calcium and magnesium rich. Therefore, it remains important for KSD patients and their physicians to realise that the mineral composition of drinking water may vary, and its consumption might require alterations of their diet.

简介:比较荷兰市售自来水和瓶装水的矿物质含量,并评估肾结石患者应选择哪种水:比较荷兰市售自来水和瓶装水的矿物质含量,评估肾结石患者应选择哪种类型的水:联系所有荷兰自来水公司,索取自来水分析报告。材料:我们联系了荷兰所有的自来水供应公司,要求提供自来水分析报告,同时还包括荷兰 5 家主要连锁超市出售的瓶装静水和气泡水。有关瓶装水矿物质成分的信息来自瓶子上的制造商成分标签。评估了有关钠、钾、碳酸氢盐、钙、镁和硫酸盐含量的数据:结果:所有荷兰供水公司(包括 179 个生产基地)均被纳入评估范围。其中包括 21 种瓶装静水和 25 种瓶装气泡水。所评估的矿物质含量差异很大。自来水中的钠含量最高(134.0 毫克/升),而瓶装水中的钾含量最高(18.0 毫克/升)。瓶装静态水的碳酸氢盐、钙和硫酸盐浓度最高(分别为 432.0 毫克/升、240.0 毫克/升和 400.0 毫克/升)。瓶装气泡水的镁含量最高(51.4 毫克/升):结论:荷兰的商用水(瓶装水和自来水)对 KSD 患者来说是安全的。然而,某些瓶装水可能富含钙和镁。因此,KSD 患者及其医生必须认识到,饮用水中的矿物质成分可能会有所不同,饮用这种水可能需要改变饮食习惯。
{"title":"What kind of water should I advise my kidney stone patient to drink: the Dutch experience.","authors":"Simone J M Stoots, Michaël M E L Henderickx, Guido M Kamphuis","doi":"10.5173/ceju.2024.42.R1","DOIUrl":"10.5173/ceju.2024.42.R1","url":null,"abstract":"<p><strong>Introduction: </strong>To compare the mineral content of commercially available water (tap and bottled) in the Netherlands and to evaluate which type of water should be recommended for kidney stone patients.</p><p><strong>Material and methods: </strong>All Dutch water supply companies were contacted to request water analysis reports of tap water. Bottled still and sparkling water available in the 5 main supermarket chains in the Netherlands were also included. Information regarding the mineral composition of bottled waters was read from the manufacturers' ingredient label on the bottles. Data regarding sodium, potassium, bicarbonate, calcium, magnesium, and sulphate content were evaluated.</p><p><strong>Results: </strong>All Dutch water supply companies, consisting of 179 production locations, were included. Twenty-one bottled still waters and 25 bottled sparkling waters were included. There was a wide range of results for the evaluated minerals. Sodium levels were highest in tap water (134.0 mg/l), whereas potassium concentrations were highest in bottled water (18.0 mg/l). Bicarbonate, calcium, and sulphate concentrations were highest in bottled still water (432.0 mg/l, 240.0 mg/l, and 400.0 mg/l, respectively). Magnesium levels were highest in bottled sparkling water (51.4 mg/l).</p><p><strong>Conclusions: </strong>Commercially available water (bottled and tap) in the Netherlands is safe to use for KSD patients. However, specific bottled waters can be described as calcium and magnesium rich. Therefore, it remains important for KSD patients and their physicians to realise that the mineral composition of drinking water may vary, and its consumption might require alterations of their diet.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"494-506"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological characteristics of 214,063 hospital admissions to adult urological departments in Poland in 2022. 2022 年波兰成人泌尿科 214,063 例住院病人的流行病学特征。
IF 1.4 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.5173/ceju.2024.55.R1
Gabriela Moczeniat, Mateusz Jankowski, Paweł Goryński, Mariusz Gujski

Introduction: Nationwide data on urological hospitalizations may improve the quality of care. This study aimed to evaluate the epidemiological characteristics of all registered hospital admissions to adult urological departments in Poland in 2022.

Material and methods: This epidemiological retrospective analysis is based on the national registry on hospital admissions managed by the National Institute of Public Health - National Research Institute. All adult patients admitted to urological departments were included in the analysis.

Results: In 2022, 214,063 hospital admissions were recorded in Polish urological departments, 72% of the patients were male. Emergency admissions accounted for 17.6% of these admissions. There were significant differences in hospitalization rate per 100,000 population between the administrative regions (voivodeships), with extreme values recorded in the Opolskie (411.5) and Podkarpackie (987.9) voivodeships. The major causes of admission were genitourinary diseases (ICD-10: N00-N99) at 59% and cancers (ICD-10: C00-C97; D00-D48) at 36%. In general, kidney and ureteral stones (19.9%), bladder cancer (15.2%), and prostate hyperplasia (10%) were the most common causes of hospital admissions. The highest hospitalization rate per 100,000 inhabitants was observed among adults aged 60-69 and 70-79 years. A quarter of hospitalizations were one-day hospitalizations, and the mean duration of hospitalization was 2.93 days for all hospitalizations, and when excluding one-day hospitalizations 3.89 days. Epidemiological characteristics of patients and duration of hospitalization differed by cause of admission.

Conclusions: Findings from this study provide precise epidemiological data on inpatient urological care in Poland. Physicians and policymakers may use this study to evaluate and improve inpatient urological care in Poland.

{"title":"Epidemiological characteristics of 214,063 hospital admissions to adult urological departments in Poland in 2022.","authors":"Gabriela Moczeniat, Mateusz Jankowski, Paweł Goryński, Mariusz Gujski","doi":"10.5173/ceju.2024.55.R1","DOIUrl":"10.5173/ceju.2024.55.R1","url":null,"abstract":"<p><strong>Introduction: </strong>Nationwide data on urological hospitalizations may improve the quality of care. This study aimed to evaluate the epidemiological characteristics of all registered hospital admissions to adult urological departments in Poland in 2022.</p><p><strong>Material and methods: </strong>This epidemiological retrospective analysis is based on the national registry on hospital admissions managed by the National Institute of Public Health - National Research Institute. All adult patients admitted to urological departments were included in the analysis.</p><p><strong>Results: </strong>In 2022, 214,063 hospital admissions were recorded in Polish urological departments, 72% of the patients were male. Emergency admissions accounted for 17.6% of these admissions. There were significant differences in hospitalization rate per 100,000 population between the administrative regions (voivodeships), with extreme values recorded in the Opolskie (411.5) and Podkarpackie (987.9) voivodeships. The major causes of admission were genitourinary diseases (ICD-10: N00-N99) at 59% and cancers (ICD-10: C00-C97; D00-D48) at 36%. In general, kidney and ureteral stones (19.9%), bladder cancer (15.2%), and prostate hyperplasia (10%) were the most common causes of hospital admissions. The highest hospitalization rate per 100,000 inhabitants was observed among adults aged 60-69 and 70-79 years. A quarter of hospitalizations were one-day hospitalizations, and the mean duration of hospitalization was 2.93 days for all hospitalizations, and when excluding one-day hospitalizations 3.89 days. Epidemiological characteristics of patients and duration of hospitalization differed by cause of admission.</p><p><strong>Conclusions: </strong>Findings from this study provide precise epidemiological data on inpatient urological care in Poland. Physicians and policymakers may use this study to evaluate and improve inpatient urological care in Poland.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"538-546"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy in nonmetastatic upper tract urothelial carcinoma with ≤pT2. 风险适应性评分模型,用于识别≤pT2的非转移性上尿路上皮癌根治性肾切除术后辅助化疗的受益者。
IF 1.4 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.5173/ceju.2024.45.R1
Sung Jun Sou, Won Ik Seo, Jae Il Chung, Hyun Seok Lee, Kweon Sik Min, Soo Jin Jung, Chan Ho Lee

Introduction: After radical nephroureterectomy (RNU), adjuvant chemotherapy (AC) is recommended in either muscle invasive or lymph node positive upper urinary tract urothelial carcinoma (UTUC). However, optimal patient selection remains to be studied. We propose a risk-adapted scoring model for selecting patients for AC in localised UTUC with ≤pT2.

Material and methods: The model was based on 7 risk factors modified from the risk stratification system in the European Association of Urology guideline for localised UTUC. Each risk factor indicated one point; total scores were used to categorise patients as at low or high risk for disease recurrence. We applied our model to 135 patients with localised UTUC with ≤pT2, who underwent RNU without AC. Recurrence-free survival and cancer-specific survival were analysed based on risk group.

Results: A risk score of ≥4 points indicated high risk (33/135 patients [24.4%]). The accuracy of predicting recurrence was 82.9% (95% confidence interval [CI]: 75.5-88.9%) with a negative predictive value of 93.1% (95% CI: 87.9-96.2%). Disease recurred in 51.5% of high-risk patients and 6.9% of low-risk patients. Multivariate analysis indicated that high-risk was independently associated with recurrence and cancer-specific death (hazard ratio [HR] = 10.20, 95% CI: 3.94-26.44%, HR = 8.72, 95% CI: 2.47-30.73%, all p <0.001, respectively).

Conclusions: The risk-adapted scoring model might be an effective way for selecting patients who may benefit from AC after RNU in nonmetastatic UTUC with ≤pT2. These results should be validated in a larger, prospective study.

导言:根治性肾切除术(RNU)后,建议对肌肉浸润性或淋巴结阳性的上尿路尿路上皮癌(UTUC)进行辅助化疗(AC)。然而,最佳患者选择仍有待研究。我们提出了一种风险适应性评分模型,用于选择≤pT2的局部UTUC患者接受抗癌治疗:该模型基于欧洲泌尿外科协会(European Association of Urology)局部 UTUC 指南中风险分层系统的 7 个风险因素。每个风险因素代表一分;总分用于将患者分为疾病复发的低风险和高风险。我们将模型应用于135例局部UTUC且≤pT2的患者,这些患者接受了RNU治疗,但没有接受AC治疗。根据风险组别对无复发生存率和癌症特异性生存率进行了分析:风险评分≥4分表示高风险(33/135名患者[24.4%])。预测复发的准确率为 82.9%(95% 置信区间 [CI]:75.5-88.9%),阴性预测值为 93.1%(95% 置信区间 [CI]:87.9-96.2%)。51.5%的高危患者和6.9%的低危患者疾病复发。多变量分析表明,高风险与复发和癌症特异性死亡独立相关(危险比 [HR] = 10.20,95% CI:3.94-26.44%,HR = 8.72,95% CI:2.47-30.73%,均为 p):对于≤pT2的非转移性UTUC,风险适应性评分模型可能是选择RNU后可能从AC中获益的患者的有效方法。这些结果应在更大规模的前瞻性研究中加以验证。
{"title":"Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy in nonmetastatic upper tract urothelial carcinoma with ≤pT2.","authors":"Sung Jun Sou, Won Ik Seo, Jae Il Chung, Hyun Seok Lee, Kweon Sik Min, Soo Jin Jung, Chan Ho Lee","doi":"10.5173/ceju.2024.45.R1","DOIUrl":"10.5173/ceju.2024.45.R1","url":null,"abstract":"<p><strong>Introduction: </strong>After radical nephroureterectomy (RNU), adjuvant chemotherapy (AC) is recommended in either muscle invasive or lymph node positive upper urinary tract urothelial carcinoma (UTUC). However, optimal patient selection remains to be studied. We propose a risk-adapted scoring model for selecting patients for AC in localised UTUC with ≤pT2.</p><p><strong>Material and methods: </strong>The model was based on 7 risk factors modified from the risk stratification system in the European Association of Urology guideline for localised UTUC. Each risk factor indicated one point; total scores were used to categorise patients as at low or high risk for disease recurrence. We applied our model to 135 patients with localised UTUC with ≤pT2, who underwent RNU without AC. Recurrence-free survival and cancer-specific survival were analysed based on risk group.</p><p><strong>Results: </strong>A risk score of ≥4 points indicated high risk (33/135 patients [24.4%]). The accuracy of predicting recurrence was 82.9% (95% confidence interval [CI]: 75.5-88.9%) with a negative predictive value of 93.1% (95% CI: 87.9-96.2%). Disease recurred in 51.5% of high-risk patients and 6.9% of low-risk patients. Multivariate analysis indicated that high-risk was independently associated with recurrence and cancer-specific death (hazard ratio [HR] = 10.20, 95% CI: 3.94-26.44%, HR = 8.72, 95% CI: 2.47-30.73%, all p <0.001, respectively).</p><p><strong>Conclusions: </strong>The risk-adapted scoring model might be an effective way for selecting patients who may benefit from AC after RNU in nonmetastatic UTUC with ≤pT2. These results should be validated in a larger, prospective study.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"389-397"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detrusor underactivity in symptomatic anterior pelvic organ prolapse. 有症状的前盆腔器官脱垂患者的逼尿肌活动不足。
IF 1.2 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.5173/ceju.2023.246
Emanuele Rubilotta, Marilena Gubbiotti, Achim Herms, Howard Goldman, Alessandro Antonelli, Matteo Balzarro

Introduction: The aim of this study was to assess the detrusor underactivity (DUA) prevalence of females with symptomatic anterior pelvic organ prolapse (POP) and to evaluate the relationship between DUA and POP stage.

Material and methods: This was a prospective study recruiting women with symptomatic anterior POP. Patients with symptomatic stage 2-4 POP quantification system (POP-Q) who underwent urodynamics (UD) between January 2018 and April 2021 were included.

Results: Data on 330 women (mean age 63.7 ±18.4 years old) with anterior vaginal wall defect were enrolled. Concomitant apical defect (uterine/vaginal vault) requiring surgical correction was diagnosed in 38 women (11.5%). DUA was found in 166 females (50.3%). In DUA women, POP-Q stage 2 was found in 45.2%, stage 3 in 50.9% and stage 4 in 76.5%. Only stage POP-Q stage 4 showed a statistically significant difference between DUA and non-DUA females (p 0.006).

Conclusions: In women with symptomatic POP, regardless of the POP-Q stage, the chance of DUA occurrence was high. DUA was diagnosed in approximately half of the women undergoing UD for symptomatic POP, and it was three-fold higher in cases of POP-Q stage 4. Due to the high incidence of DUA in POP-Q 4 stage, it may be advantageous to identify and treat prolapse before they progress to stage 4.

导言:本研究旨在评估有症状的前盆腔器官脱垂(POP)女性的逼尿肌活动不足(DUA)患病率,并评估DUA与POP分期之间的关系:这是一项前瞻性研究,招募了患有症状性前盆腔器官脱垂的女性。纳入了在2018年1月至2021年4月期间接受尿动力学检查(UD)的无症状2-4期POP定量系统(POP-Q)患者:共纳入了 330 名阴道前壁缺损妇女(平均年龄为 63.7 ± 18.4 岁)的数据。38名妇女(11.5%)被诊断出合并需要手术矫正的顶端缺损(子宫/阴道穹窿)。166名女性(50.3%)被发现患有阴道前壁缺损。在 DUA 女性中,发现 POP-Q 2 期的占 45.2%,3 期的占 50.9%,4 期的占 76.5%。只有 POP-Q 第 4 阶段在 DUA 和非 DUA 女性中显示出显著的统计学差异(P 0.006):结论:在有症状的 POP 女性中,无论 POP-Q 分期如何,发生 DUA 的几率都很高。约有一半因有症状的 POP 而接受 UD 的女性被诊断出 DUA,而在 POP-Q 4 期的病例中,DUA 的发生率要高出三倍。由于 POP-Q 4 期的 DUA 发生率很高,因此在进展到 4 期之前发现并治疗脱垂可能是有利的。
{"title":"Detrusor underactivity in symptomatic anterior pelvic organ prolapse.","authors":"Emanuele Rubilotta, Marilena Gubbiotti, Achim Herms, Howard Goldman, Alessandro Antonelli, Matteo Balzarro","doi":"10.5173/ceju.2023.246","DOIUrl":"https://doi.org/10.5173/ceju.2023.246","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to assess the detrusor underactivity (DUA) prevalence of females with symptomatic anterior pelvic organ prolapse (POP) and to evaluate the relationship between DUA and POP stage.</p><p><strong>Material and methods: </strong>This was a prospective study recruiting women with symptomatic anterior POP. Patients with symptomatic stage 2-4 POP quantification system (POP-Q) who underwent urodynamics (UD) between January 2018 and April 2021 were included.</p><p><strong>Results: </strong>Data on 330 women (mean age 63.7 ±18.4 years old) with anterior vaginal wall defect were enrolled. Concomitant apical defect (uterine/vaginal vault) requiring surgical correction was diagnosed in 38 women (11.5%). DUA was found in 166 females (50.3%). In DUA women, POP-Q stage 2 was found in 45.2%, stage 3 in 50.9% and stage 4 in 76.5%. Only stage POP-Q stage 4 showed a statistically significant difference between DUA and non-DUA females (p 0.006).</p><p><strong>Conclusions: </strong>In women with symptomatic POP, regardless of the POP-Q stage, the chance of DUA occurrence was high. DUA was diagnosed in approximately half of the women undergoing UD for symptomatic POP, and it was three-fold higher in cases of POP-Q stage 4. Due to the high incidence of DUA in POP-Q 4 stage, it may be advantageous to identify and treat prolapse before they progress to stage 4.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 1","pages":"77-81"},"PeriodicalIF":1.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heavy as a rock or light as dust: a comparison between the perceived workload for extracorporeal shockwave lithotripsy, ureterorenoscopy and percutaneous nephrolithotomy. 重如磐石还是轻如尘埃:体外冲击波碎石术、输尿管镜检查和经皮肾镜碎石术的工作量比较。
IF 1.2 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-26 DOI: 10.5173/ceju.2023.214
Michaël Mel Henderickx, Nora Hendriks, A Carolien Bouma-Houwert, Joyce Baard, Guido M Kamphuis, Hugo W Schuil, Harrie P Beerlage, D Martijn de Bruin

Introduction: There are three common treatment options for kidney stones: extracorporeal shockwave lithotripsy (ESWL), ureterorenoscopy (URS) and percutaneous nephrolithotomy (PNL). The choice of treatment is based on stone- and patient-related characteristics. However, some stones are eligible for several approaches and the decision is made based on patient and urologist's preferences. This study evaluates which approach has the highest workload.

Material and methods: Between March and August 2022, five members of the Amsterdam Endourology Research Group collected data from 22 ESWL, 31 URS and 22 PNL procedures. After each procedure, the SURG-TLX questionnaire was completed by the surgeon to evaluate workload. Six dimensions were scored for each procedure, including: mental demands, physical demands, temporal demands, task complexity, situational stress, and distractions. The total workload, and the median for each dimension, was calculated and compared for the three treatments.

Results: ESWL scored significantly lower than URS for mental demands, physical demands, temporal demands, situational stress, distraction and total workload. However, task complexity did not differ significantly between the two techniques. Compared with PNL, ESWL scored significantly lower for all dimensions. Finally, PNL received significantly higher scores for mental demands, physical demands, temporal demands, situational stress, distractions and total workload than URS. Only task complexity showed no significant difference between both groups.

Conclusions: Urologists perceive the highest workload during PNL, followed by URS and finally ESWL. A follow-up study is needed to identify stressors that increase perceived workload with the purpose to address these variables and as final objective to improve urologists' workload, patient safety and treatment outcomes.

导言:肾结石有三种常见的治疗方法:体外冲击波碎石(ESWL)、输尿管镜检查(URS)和经皮肾镜碎石术(PNL)。治疗方法的选择取决于结石和患者的相关特征。不过,有些结石可采用多种方法治疗,因此要根据患者和泌尿科医生的喜好来决定。本研究评估了哪种方法的工作量最大:2022 年 3 月至 8 月间,阿姆斯特丹腔内泌尿学研究小组的五名成员收集了 22 例 ESWL、31 例 URS 和 22 例 PNL 手术的数据。每次手术后,外科医生都要填写 SURG-TLX 问卷,以评估工作量。每项手术都有六个方面的评分,包括:精神需求、体力需求、时间需求、任务复杂性、情境压力和分心。计算并比较了三种治疗方法的总工作量和每个维度的中位数:结果:ESWL 在精神需求、体力需求、时间需求、情境压力、分心和总工作量方面的得分明显低于 URS。然而,两种技术的任务复杂性并无明显差异。与 PNL 相比,ESWL 在所有方面的得分都明显较低。最后,PNL 在心理需求、生理需求、时间需求、情境压力、注意力分散和总工作量方面的得分都明显高于 URS。只有任务复杂性在两组之间没有明显差异:结论:泌尿科医生在 PNL 过程中的工作量最大,其次是 URS,最后是 ESWL。需要进行后续研究,以确定增加感知工作量的压力因素,从而解决这些变量,并将改善泌尿科医生的工作量、患者安全和治疗效果作为最终目标。
{"title":"Heavy as a rock or light as dust: a comparison between the perceived workload for extracorporeal shockwave lithotripsy, ureterorenoscopy and percutaneous nephrolithotomy.","authors":"Michaël Mel Henderickx, Nora Hendriks, A Carolien Bouma-Houwert, Joyce Baard, Guido M Kamphuis, Hugo W Schuil, Harrie P Beerlage, D Martijn de Bruin","doi":"10.5173/ceju.2023.214","DOIUrl":"https://doi.org/10.5173/ceju.2023.214","url":null,"abstract":"<p><strong>Introduction: </strong>There are three common treatment options for kidney stones: extracorporeal shockwave lithotripsy (ESWL), ureterorenoscopy (URS) and percutaneous nephrolithotomy (PNL). The choice of treatment is based on stone- and patient-related characteristics. However, some stones are eligible for several approaches and the decision is made based on patient and urologist's preferences. This study evaluates which approach has the highest workload.</p><p><strong>Material and methods: </strong>Between March and August 2022, five members of the Amsterdam Endourology Research Group collected data from 22 ESWL, 31 URS and 22 PNL procedures. After each procedure, the SURG-TLX questionnaire was completed by the surgeon to evaluate workload. Six dimensions were scored for each procedure, including: mental demands, physical demands, temporal demands, task complexity, situational stress, and distractions. The total workload, and the median for each dimension, was calculated and compared for the three treatments.</p><p><strong>Results: </strong>ESWL scored significantly lower than URS for mental demands, physical demands, temporal demands, situational stress, distraction and total workload. However, task complexity did not differ significantly between the two techniques. Compared with PNL, ESWL scored significantly lower for all dimensions. Finally, PNL received significantly higher scores for mental demands, physical demands, temporal demands, situational stress, distractions and total workload than URS. Only task complexity showed no significant difference between both groups.</p><p><strong>Conclusions: </strong>Urologists perceive the highest workload during PNL, followed by URS and finally ESWL. A follow-up study is needed to identify stressors that increase perceived workload with the purpose to address these variables and as final objective to improve urologists' workload, patient safety and treatment outcomes.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 1","pages":"129-135"},"PeriodicalIF":1.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of combination therapy tadalafil plus tamsulosin in ureteral stents-related symptoms relief. 他达拉非加坦索罗辛联合疗法对缓解输尿管支架相关症状的疗效。
IF 1.2 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2023-11-20 DOI: 10.5173/ceju.2023.66
Ihor Komisarenko, Oleg Banyra, Oleg Nikitin, Yaroslav Klymenko, Mykola Chaplia, Andrii Borzhievskyy

Introduction: Ureteral stents-related symptoms (USRs) are the common complications of ureteral stenting. Tamsulosin a selective alpha-1 blocker and Tadalafil a PDE-5 inhibitor are one of drugs have been used for USRs relief. In this study we aimed to evaluate the effectiveness and safety of combination therapy Tamsulosin+Tadalafil for treating USRs comparing it with the efficacy of either Tamsulosin or Tadalafil monotherapies.

Material and methods: 279 patients with indwelled unilateral ureteral stents were randomized to Tamsulosin 0.4 mg + Tadalafil 5 mg once a day (Group 1, n = 67), Tamsulosin 0.4 mg once a day (Group 2, n = 71), Tadalafil 5 mg once a day (Group 3, n = 69) and Placebo once a day (Group 4, n = 72). USRs severity was registered and calculated by using the Ureteral Symptoms Score Questionnaire (USSQ) at the 14th day of treatment. Side-effects and total analgesic use were recorded and compared.

Results: At the endpoint in patients with unilateral ureteral stents the combination therapy Tamsulosin + Tadalafil led to statistically lower intensity of urinary symptoms comparing with Tamsulosin (15.2 ±4.3 vs 21.8±3.6, p = 0.0003) or Tadalafil (15.2 ±4.3 vs 20.6 ±2.8, p = 0.0004) monotherapy. All groups of treatment demonstrated significant relief of USRs comparing with Placebo mostly beneficial in the combined therapy group. Body pain and analgesic need in Group 1 was lower than in Groups 2, 3 or 4. Side-effects were registered rarely without statistical differences in frequency between groups.

Conclusions: Combination therapy with Tamsulosin + Tadalafil is an effective and safe option that achieves the statistically more significant relief of USRs comparing with Tadalafil or Tamsulosin monotherapies.

导言:输尿管支架相关症状(USRs)是输尿管支架植入术的常见并发症。选择性α-1受体阻滞剂坦索罗辛(Tamsulosin)和PDE-5抑制剂他达拉非(Tadalafil)是缓解输尿管支架相关症状的药物之一。本研究旨在评估坦索罗辛+他达拉非联合疗法治疗 USR 的有效性和安全性,并与坦索罗辛或他达拉非单一疗法的疗效进行比较。材料和方法:279 名单侧留置输尿管支架的患者被随机分为坦索罗辛 0.4 毫克+他达拉非 5 毫克每天一次(第 1 组,n = 67)、坦索罗辛 0.4 毫克每天一次(第 2 组,n = 71)、他达拉非 5 毫克每天一次(第 3 组,n = 69)和安慰剂每天一次(第 4 组,n = 72)。在治疗的第14天,使用输尿管症状评分问卷(USSQ)登记并计算USRs的严重程度。对副作用和镇痛剂总用量进行了记录和比较:结果:在单侧输尿管支架患者的终点,坦索罗辛+他达拉非联合疗法与坦索罗辛(15.2 ±4.3 vs 21.8±3.6,p = 0.0003)或他达拉非(15.2 ±4.3 vs 20.6 ±2.8,p = 0.0004)单药疗法相比,排尿症状强度明显降低。与安慰剂相比,所有治疗组的 USR 均有明显缓解,其中以联合治疗组最为明显。第 1 组的身体疼痛和镇痛需求低于第 2、3 或 4 组。副作用极少,组间频率无统计学差异:结论:与他达拉非或坦索罗辛单一疗法相比,坦索罗辛+他达拉非联合疗法是一种有效而安全的选择,能在统计学上更显著地缓解USR。
{"title":"Efficacy of combination therapy tadalafil plus tamsulosin in ureteral stents-related symptoms relief.","authors":"Ihor Komisarenko, Oleg Banyra, Oleg Nikitin, Yaroslav Klymenko, Mykola Chaplia, Andrii Borzhievskyy","doi":"10.5173/ceju.2023.66","DOIUrl":"https://doi.org/10.5173/ceju.2023.66","url":null,"abstract":"<p><strong>Introduction: </strong>Ureteral stents-related symptoms (USRs) are the common complications of ureteral stenting. Tamsulosin a selective alpha-1 blocker and Tadalafil a PDE-5 inhibitor are one of drugs have been used for USRs relief. In this study we aimed to evaluate the effectiveness and safety of combination therapy Tamsulosin+Tadalafil for treating USRs comparing it with the efficacy of either Tamsulosin or Tadalafil monotherapies.</p><p><strong>Material and methods: </strong>279 patients with indwelled unilateral ureteral stents were randomized to Tamsulosin 0.4 mg + Tadalafil 5 mg once a day (Group 1, n = 67), Tamsulosin 0.4 mg once a day (Group 2, n = 71), Tadalafil 5 mg once a day (Group 3, n = 69) and Placebo once a day (Group 4, n = 72). USRs severity was registered and calculated by using the Ureteral Symptoms Score Questionnaire (USSQ) at the 14<sup>th</sup> day of treatment. Side-effects and total analgesic use were recorded and compared.</p><p><strong>Results: </strong>At the endpoint in patients with unilateral ureteral stents the combination therapy Tamsulosin + Tadalafil led to statistically lower intensity of urinary symptoms comparing with Tamsulosin (15.2 ±4.3 vs 21.8±3.6, p = 0.0003) or Tadalafil (15.2 ±4.3 vs 20.6 ±2.8, p = 0.0004) monotherapy. All groups of treatment demonstrated significant relief of USRs comparing with Placebo mostly beneficial in the combined therapy group. Body pain and analgesic need in Group 1 was lower than in Groups 2, 3 or 4. Side-effects were registered rarely without statistical differences in frequency between groups.</p><p><strong>Conclusions: </strong>Combination therapy with Tamsulosin + Tadalafil is an effective and safe option that achieves the statistically more significant relief of USRs comparing with Tadalafil or Tamsulosin monotherapies.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 1","pages":"111-116"},"PeriodicalIF":1.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of PARP inhibitors in prostate cancer.
IF 1.4 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-28 DOI: 10.5173/ceju.2024.72.R1
Julia Szczotka, Gabriela Szpila, Michał Hejduk, Ewa Mucha, Jolanta Rudel, Michał Kępiński, Julia Kaletka, Jakub Ryszawy, Piotr Zapala, Ichiro Tsuboi, Akihiro Matsukawa, Marcin Miszczyk, Tamas Fazekas, Fabio Zattoni, Piotr Bryniarski, Paweł Rajwa

Introduction: Olaparib, rucaparib, niraparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) targeted at recombination. To gain a comprehensive understanding of the mechanism of action of PARPi, scientists conducted research involving numerous studies that provided evidence regarding their efficacy and safety.

Material and methods: A literature review was performed using the PubMed® and Google Scholar databases. Articles were reviewed and categorized based on the most crucial and current information regarding the pharmacological properties and use of PARPi in treating metastatic castration-resistant prostate cancer (mCRPC), while also indicating the future therapeutic direction toward which these pharmaceuticals are progressing. Data were extracted, analyzed and summarized.

Results: PARP inhibitors like olaparib, rucaparib, niraparib, and talazoparib show promise in mCRPC, particularly for patients with specific genetic mutations (BRCA1/2, ATM). While they extend PFS and sometimes OS, side effects - especially anemia - are prevalent and impact treatment continuation.

Conclusions: Despite PARPi already being recognized as the standard treatment for mCRPC, further research is crucial to optimize their efficacy and safety, particularly in the context of combination therapies and use in the early stages of the disease.

{"title":"Role of PARP inhibitors in prostate cancer.","authors":"Julia Szczotka, Gabriela Szpila, Michał Hejduk, Ewa Mucha, Jolanta Rudel, Michał Kępiński, Julia Kaletka, Jakub Ryszawy, Piotr Zapala, Ichiro Tsuboi, Akihiro Matsukawa, Marcin Miszczyk, Tamas Fazekas, Fabio Zattoni, Piotr Bryniarski, Paweł Rajwa","doi":"10.5173/ceju.2024.72.R1","DOIUrl":"10.5173/ceju.2024.72.R1","url":null,"abstract":"<p><strong>Introduction: </strong>Olaparib, rucaparib, niraparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) targeted at recombination. To gain a comprehensive understanding of the mechanism of action of PARPi, scientists conducted research involving numerous studies that provided evidence regarding their efficacy and safety.</p><p><strong>Material and methods: </strong>A literature review was performed using the PubMed<sup>®</sup> and Google Scholar databases. Articles were reviewed and categorized based on the most crucial and current information regarding the pharmacological properties and use of PARPi in treating metastatic castration-resistant prostate cancer (mCRPC), while also indicating the future therapeutic direction toward which these pharmaceuticals are progressing. Data were extracted, analyzed and summarized.</p><p><strong>Results: </strong>PARP inhibitors like olaparib, rucaparib, niraparib, and talazoparib show promise in mCRPC, particularly for patients with specific genetic mutations (<i>BRCA1/2, ATM</i>). While they extend PFS and sometimes OS, side effects - especially anemia - are prevalent and impact treatment continuation.</p><p><strong>Conclusions: </strong>Despite PARPi already being recognized as the standard treatment for mCRPC, further research is crucial to optimize their efficacy and safety, particularly in the context of combination therapies and use in the early stages of the disease.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"424-435"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Central European Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1